Cisplatin-Induced Ototoxicity in Pediatric Solid Tumors

Disease Burden Assessment

Respondents reported a high incidence of hearing loss among pediatric patients treated with cisplatin.

Awareness vs. Action Gap

Substantial variability in preventive and management strategies was observed across countries.

Incidence Variability

Clinician-reported incidence varies based on definition of clinically meaningful hearing loss.

Risk Stratification Insights

Cisplatin-associated ototoxicity remains a critical yet unresolved issue in pediatric oncology.

Sodium Thiosulfate Adoption Signals

Sodium thiosulfate-based therapy has emerged as a potential strategy to reduce cisplatin-induced ototoxicity in the localized, non-metastatic setting, but certain clinical and pharmacological limitations remain.

Strategic Implications

These study findings highlight a strategic opportunity for novel interventions that preserve antitumor efficacy while reducing treatment-related toxicity, supported by robust safety data and country-specific implementation frameworks.